Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA approves new Alzheimer's PET imaging agent from Lantheus

14 August 2026 · By · Wire by Fusion42

Published

14 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at radiologybusiness.com →

◆ Verified

Fusion42 · 14 August 2026 · Fusion42 review

The U.S. FDA has approved a new PET imaging agent from Lantheus specifically for Alzheimer's disease, enabling improved diagnosis and patient management.

This Wire brief sits within Fusion42's coverage of Medtech, and 4 sources have reported it between 14 Aug 2026 and 15 Aug 2026.

◆ ◆ The Wire takeaway

Medtech founders in brain imaging should move to integrate or support Lantheus's approved PET agent to access the US Alzheimer's diagnostic market. This FDA approval widens a critical clinical tool that now demands supply and service innovation around it.

◆ Coverage

4 sources · first reported 14 Aug 2026 · latest 15 Aug 2026

◆ Related on Wire

◆ Topics

MedtechFDA-approvalalzheimersPET-imagingdiagnosticsLantheus